National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 10) (No. PB 102 of 2014)

Link to law: https://www.comlaw.gov.au/Details/F2014L01834

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 102 of 2014
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 10)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated           22   December 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________________
 
 
1       Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.10).
 
(2)                This Instrument may also be cited as PB 102 of 2014.
 
2              Commencement
This Instrument commences on 1 January 2015.
3              Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
 
 
Schedule 1       Amendments
[1]           Schedule 1, entry Clarithromycin in each of the forms: Tablet 250 mg; and Tablet 500 mg
omit from the column headed “Responsible Person”:                AB                                substitute:      GO
[2]           Schedule 1, entry for Epoetin Lambda in each of the forms: Injection 1,000 units in 0.5 mL pre-filled syringe; Injection 2,000 units in 1 mL pre-filled syringe; Injection 3,000 units in 0.3 mL pre-filled syringe; Injection 4,000 units in 0.4 mL pre-filled syringe; Injection 5,000 units in 0.5 mL pre-filled syringe; Injection 6,000 units in 0.6 mL pre-filled syringe; Injection 8,000 units in 0.8 mL pre-filled syringe; and Injection 10,000 units in 1 mL pre-filled syringe
omit from the column headed “Responsible Person”:                NV                                substitute:      SZ
[3]           Schedule 1, entry for Sildenafil
 
 
 
SILDENAFIL-DRx
RZ
EMP
C4608 C4615
C4621 C4636
C4641
 
See Note 1
See Note 2
D
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
[4]           Schedule 2, for details relevant to Responsible Person Code AB
omit:
AB
Abbott Australasia Pty Ltd
 95 000 180 389
[5]           Schedule 2, after details relevant to Responsible Person code GN
insert:
GO
BGP Products Pty Ltd
 29 601 608 771
[6]           Schedule 2, after details relevant to Responsible Person code RO
insert:
RZ
Dr Reddy’s Laboratories Australia Pty Ltd
 16 120 092 408